Bayer's Fortnight of Reckoning: A Legal Cliffhanger and a Financial Reckoning

Bayer stock faces a pivotal two weeks with its AGM, dividend vote, and a landmark U.S. Supreme Court hearing on Roundup litigation that could redefine its legal risk.

Bayer shares, having nearly doubled over the past twelve months, are entering a critical two-week period that will test the durability of its recovery. The stock closed Friday at EUR 41.10, trading precisely on its 50-day moving average, as investors brace for a series of high-stakes events spanning corporate strategy, shareholder returns, and a landmark legal battle.

The immediate focus is on the company's annual general meeting. Shareholders have until midnight Saturday to submit questions for the virtual event on April 24. The management board, led by CEO Bill Anderson, will face investors with a proposal to pay an unchanged dividend of EUR 0.11 per share. If approved, the payout will reach investor accounts on April 29. Ahead of this, the company will publish the speech manuscripts of Anderson and Supervisory Board Chairman Norbert Winkeljohann on Monday evening, offering early clues to the strategic direction.

While shareholder events unfold, a seismic legal challenge looms. On April 27, the U.S. Supreme Court will hear oral arguments in the pivotal Roundup case, Durnell. This proceeding is viewed as a potential watershed, capable of redefining the long-term litigation risks stemming from the Monsanto acquisition. The outcome could trigger a comprehensive reassessment of Bayer's legal liabilities, injecting significant volatility into the stock.

Amidst these events, analysts are recalibrating their views. Deutsche Bank has issued a radical update, more than doubling its price target on Bayer from EUR 23 to EUR 43, though it maintains a "Hold" rating. Analyst Virginie Boucher-Ferte forecasts organic growth of nearly four percent for the upcoming quarter, driven primarily by the Crop Science division. She expects license revenues in the high triple-digit millions from this unit to cushion current pharmaceutical weakness, projecting a slight decline in adjusted operating profit for the first quarter.

The pharmaceutical business itself is in a state of transition. The company views 2026 as the final year of significant headwind from patent expirations for blockbusters Xarelto and Eylea, targeting a return to mid-single-digit growth in the division thereafter. This optimism is fueled by a promising pipeline. The cancer drug Nubeqa saw revenue surge 57 percent to EUR 2.4 billion recently, while the kidney medicine Kerendia delivered even steeper percentage growth, providing crucial operational stability. In the background, the hopeful stroke prevention drug Asundexian continues to deliver positive clinical data, forming a foundation to lift the operational margin toward 30 percent by the end of the decade.

Financially, the company is making headway, having reduced its net financial debt by roughly 8.5 percent to just under EUR 30 billion by the end of 2025. The coming fortnight, however, presents a dual test: the market will weigh these operational and financial improvements against the unresolved and potentially monumental legal risk now before America's highest court.